Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$279.11 -0.4%	$281.02	$253.30 ▼ $346.85	$150.75B	0.51	2.82 million shs	3.00 million shs
CORT Corcept Therapeutics	$74.33 +0.5%	$72.27	$29.42 ▼ $117.33	$7.85B	0.19	1.13 million shs	778,609 shs
GILD Gilead Sciences	$107.62 +1.6%	$106.27	$66.01 ▼ $119.96	$131.77B	0.29	7.61 million shs	6.31 million shs
MRK Merck & Co., Inc.	$78.94 -0.9%	$79.04	$73.31 ▼ $132.29	$200.05B	0.38	13.09 million shs	13.74 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	-0.44%	-3.63%	-0.12%	-9.07%	-10.78%
CORT Corcept Therapeutics	+0.46%	+4.34%	-3.23%	+36.06%	+135.22%
GILD Gilead Sciences	+1.60%	-0.35%	-1.35%	-3.73%	+55.27%
MRK Merck & Co., Inc.	-1.01%	-0.41%	+1.85%	-11.49%	-39.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMGN Amgen	4.3945 of 5 stars	2.2	4.0	3.3	3.9	2.8	2.5	0.6
CORT Corcept Therapeutics	4.6495 of 5 stars	3.5	1.0	0.0	4.2	2.9	4.2	1.9
GILD Gilead Sciences	4.9061 of 5 stars	1.4	5.0	4.2	4.1	4.0	2.5	3.1
MRK Merck & Co., Inc.	4.9985 of 5 stars	3.2	5.0	5.0	3.9	3.0	2.5	3.8

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.35	Hold	$307.82	10.29% Upside
CORT Corcept Therapeutics	3.00	Buy	$138.25	85.99% Upside
GILD Gilead Sciences	2.78	Moderate Buy	$110.55	2.72% Upside
MRK Merck & Co., Inc.	2.43	Hold	$109.19	38.32% Upside

Current Analyst Ratings Breakdown

Latest MRK, AMGN, CORT, and GILD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	AMGN Amgen	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/24/2025	AMGN Amgen	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$305.00
5/21/2025	GILD Gilead Sciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/20/2025	MRK Merck & Co., Inc.	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Cautious
5/20/2025	AMGN Amgen	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$288.00
5/16/2025	AMGN Amgen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$329.00 ➝ $328.00
5/14/2025	MRK Merck & Co., Inc.	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$115.00 ➝ $84.00
5/8/2025	AMGN Amgen	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/7/2025	AMGN Amgen	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$235.00 ➝ $280.00
5/6/2025	CORT Corcept Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$135.00
5/6/2025	CORT Corcept Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$150.00 ➝ $145.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$33.42B	4.49	$30.24 per share	9.23	$10.93 per share	25.54
CORT Corcept Therapeutics	$675.04M	11.68	$1.25 per share	59.57	$6.49 per share	11.45
GILD Gilead Sciences	$28.75B	4.66	$6.98 per share	15.42	$15.44 per share	6.97
MRK Merck & Co., Inc.	$64.17B	3.09	$9.37 per share	8.42	$18.33 per share	4.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$4.09B	$10.96	25.47	13.05	2.54	17.39%	176.11%	12.39%	8/5/2025 (Estimated)
CORT Corcept Therapeutics	$141.21M	$1.16	64.08	40.18	N/A	19.33%	20.40%	16.64%	8/4/2025 (Estimated)
GILD Gilead Sciences	$480M	$4.75	22.66	13.27	0.69	20.76%	51.93%	17.40%	8/6/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.87	11.49	7.97	0.83	27.27%	43.23%	17.11%	7/29/2025 (Estimated)

Latest MRK, AMGN, CORT, and GILD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/5/2025	Q1 2025	CORT Corcept Therapeutics	$0.17	$0.17	N/A	$0.17	$177.93 million	$157.21 million
5/1/2025	Q1 2025	AMGN Amgen	$4.18	$4.90	+$0.72	$3.20	$8.05 billion	$8.15 billion
4/24/2025	Q1 2025	GILD Gilead Sciences	$1.77	$1.81	+$0.04	$1.04	$6.77 billion	$6.67 billion
4/24/2025	Q1 2025	MRK Merck & Co., Inc.	$2.16	$2.22	+$0.06	$2.01	$15.59 billion	$15.53 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$9.52	3.41%	N/A	86.86%	14 Years
CORT Corcept Therapeutics	N/A	N/A	N/A	N/A	N/A
GILD Gilead Sciences	$3.16	2.94%	N/A	66.53%	10 Years
MRK Merck & Co., Inc.	$3.24	4.10%	N/A	47.16%	14 Years

Latest MRK, AMGN, CORT, and GILD Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/27/2025	MRK Merck & Co., Inc.	quarterly	$0.81	4.18%	6/16/2025	6/16/2025	7/8/2025
4/22/2025	GILD Gilead Sciences	quarterly	$0.79	3%	6/13/2025	6/13/2025	6/27/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	8.70	1.17	0.88
CORT Corcept Therapeutics	N/A	3.07	2.96
GILD Gilead Sciences	1.16	1.37	1.23
MRK Merck & Co., Inc.	0.69	1.41	1.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
CORT Corcept Therapeutics	93.61%
GILD Gilead Sciences	83.67%
MRK Merck & Co., Inc.	76.07%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.76%
CORT Corcept Therapeutics	20.80%
GILD Gilead Sciences	0.27%
MRK Merck & Co., Inc.	0.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	28,000	537.71 million	533.62 million	Optionable
CORT Corcept Therapeutics	300	106.04 million	83.99 million	Optionable
GILD Gilead Sciences	17,600	1.24 billion	1.24 billion	Optionable
MRK Merck & Co., Inc.	75,000	2.51 billion	2.51 billion	Optionable

MRK, AMGN, CORT, and GILD Headlines

Recent News About These Companies

Perpetual Ltd Has $59.42 Million Position in Merck & Co., Inc. (NYSE:MRK)

1 hour ago | marketbeat.com

Creative Financial Designs Inc. ADV Grows Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

2 hours ago | marketbeat.com

Perigon Wealth Management LLC Has $6.11 Million Stock Position in Merck & Co., Inc. (NYSE:MRK)

2 hours ago | marketbeat.com

MRK - Merck & Co Inc Key Metrics - Morningstar

June 26 at 8:11 PM | morningstar.comM

Merck (MRK) Stock Falls Amid Market Uptick: What Investors Need to Know

June 26 at 6:51 PM | zacks.com

ACIP Recommends Use of Merck's ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season

June 26 at 1:39 PM | businesswire.com

Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?

June 26 at 10:51 AM | zacks.com

RFK Jr.’s Advisers Back Merck’s RSV Shot for Newborns

June 26 at 10:08 AM | bloomberg.com

RFK Jr.'s CDC vaccine panel backs Merck RSV shot for infants

June 26 at 10:03 AM | cnbc.com

ACIP recommends Merck's RSV shot for infants under 8 months old

June 26 at 10:01 AM | youtube.comY

US CDC panel votes in favor of Merck's RSV antibody drug

June 26 at 9:00 AM | reuters.com

Baugh & Associates LLC Acquires 10,094 Shares of Merck & Co., Inc. (NYSE:MRK)

June 26 at 7:21 AM | marketbeat.com

KPP Advisory Services LLC Increases Stake in Merck & Co., Inc. (NYSE:MRK)

June 26 at 7:20 AM | marketbeat.com

Penobscot Investment Management Company Inc. Raises Stock Position in Merck & Co., Inc. (NYSE:MRK)

June 26 at 7:02 AM | marketbeat.com

Merck & Co., Inc. (NYSE:MRK) Stake Reduced by Robeco Institutional Asset Management B.V.

June 26 at 6:42 AM | marketbeat.com

Merck & Co., Inc. (NYSE:MRK) Shares Sold by Sequoia Financial Advisors LLC

June 26 at 6:34 AM | marketbeat.com

Aspetuck Financial Management LLC Purchases Shares of 7,686 Merck & Co., Inc. (NYSE:MRK)

June 26 at 6:23 AM | marketbeat.com

Security National Bank Decreases Stake in Merck & Co., Inc. (NYSE:MRK)

June 26 at 6:14 AM | marketbeat.com

Merck & Co., Inc. (NYSE:MRK) Position Trimmed by Phillips Wealth Planners LLC

June 26 at 6:13 AM | marketbeat.com

Golden State Wealth Management LLC Boosts Stake in Merck & Co., Inc. (NYSE:MRK)

June 26 at 5:30 AM | marketbeat.com

Strategic Investment Advisors MI Decreases Stock Position in Merck & Co., Inc. (NYSE:MRK)

June 26 at 4:54 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRK, AMGN, CORT, and GILD Company Descriptions

Amgen NASDAQ:AMGN

$279.11 -1.24 (-0.44%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$280.26 +1.15 (+0.41%)

As of 06:28 AM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Corcept Therapeutics NASDAQ:CORT

$74.33 +0.34 (+0.46%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$74.25 -0.08 (-0.11%)

As of 06:16 AM Eastern

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Gilead Sciences NASDAQ:GILD

$107.62 +1.69 (+1.60%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$107.83 +0.21 (+0.20%)

As of 06:11 AM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Merck & Co., Inc. NYSE:MRK

$78.94 -0.73 (-0.92%)

Closing price 06/26/2025 03:59 PM Eastern

Extended Trading

$79.04 +0.10 (+0.13%)

As of 06:29 AM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time